Profile: Aptinyx Inc (APTX.OQ)
21 May 2019
Aptinyx Inc., incorporated on June 24, 2015, is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor.
The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy and fibromyalgia. It is also developing NYX-783, an NMDA receptor for the treatment of post-traumatic stress disorder and NYX-458 to treat Parkinson’s disease cognitive impairment. The Company, in partnership with Allergan plc develops AGN-241751 for major depressive disorder indications.
The Company competes with AmKor Pharma, Inc., Avanir Pharmaceuticals, Inc., Axsome Therapeutics, Inc., Biohaven Pharmaceutical Holding Co. Ltd., Cadent Therapeutics, Inc., Cerecor Inc., Eli Lilly and Company, Genentech Inc., Immune Pharmaceuticals Inc., Intra-Cellular Therapies, Inc., Janssen Pharmaceuticals, Inc., NeuroRx, Inc., Newron Pharmaceuticals S.p.A., Otonomy, Inc., Relmada Therapeutics, Inc., Sage Therapeutics, Inc., UCB S.A., Vistagen Therapeutics, Inc., Biogen Inc., Cara Therapeutics, Inc., Daiichi Sankyo Company, Immune Pharmaceuticals Inc., Novartis AG, and Xenoport Inc.
1801 Maple Ave Ste 4300
EVANSTON IL 60201-3149